Showing 831-840 of 1039 results for "".
Bimekizumab-bkzx Journal Scan: 4 Clinical Trials
https://practicaldermatology.com/topics/digital-supplement/bimekizumab-bkzx-journal-scan-4-clinical-trials/24128/Speed, depth, and durability from the first dual IL-17A/F inhibitor for the treatment of moderate to severe plaque psoriasis.Optimizing Patient Experience With Photodynamic Therapy
https://practicaldermatology.com/issues/supplements/optimizing-patient-experience-with-photodynamic-therapy/23972/As diagnoses of actinic keratosis rise, so has access to photodynamic therapy—making clear, compassionate communication a critical component of overall patient experience.BPO and Alternative Acne Options
https://practicaldermatology.com/issues/july-2025/bpo-alternative-acne-options/36505/Acne treatments have been in the spotlight more than usual recently, as Valisure and the US Food and Drug Administration (FDA) have examined benzoyl peroxide (BPO) products for benzene contamination. At the same time, innovative new options are becoming available. Practical Dermatology spoke to DianRosacea Update: A Closer Look at Zilxi
https://practicaldermatology.com/columns/clinical-focus-1/rosacea-update-a-closer-look-at-zilxi/23339/Inside the approval of Zilxi for moderate-to-severe facial papulopustular rosacea.Dermatologists Give AI A Thumbs Up
https://practicaldermatology.com/topics/practice-management/dermatologists-give-ai-a-thumbs-up/23673/Dr. Vishal Patel talks augmented intelligence and how it may change practice.One-and-Done Tattoo Removal: Is It Possible With Q-switched Technology?
https://practicaldermatology.com/topics/practice-management/one-and-done-tattoo-removal-is-it-possible-with-q-switched-technology/21019/Newer and more powerful nanosecond lasers coupled with improved techniques have greatly improved the ability to clear tattoos faster and treat resistant colors.It’s A Hit! CSF Takes to Music City
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/its-a-hit-csf-takes-to-music-city/23199/If you weren’t at the meeting in Nashville, here’s what you missed.Understanding a New Method of Assessing Psoriasis Severity
https://practicaldermatology.com/columns/clinical-focus-1/understanding-a-new-method-of-assessing-psoriasis-severity/23157/New method aims to improve access to systemic psoriasis therapy.Physician Spotlight: Steven R. Feldman, MD, PhD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-steven-r-feldman-md-phd/20541/The new thinking on improving adherence in dermatology.Upadacitinib and Cardiovascular Events in AD
https://practicaldermatology.com/issues/october-2025/upadacitinib-and-cardiovascular-events-in-ad/39755/A recent review examined whether upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor approved for atopic dermatitis (AD) and other chronic inflammatory diseases, may—despite a boxed warning to the contrary—confer cardioprotective and thromboprotective effects.